ProteinSimple Launches New System for Protein Biologics
Santa Clara, CA, October 6, 2011 — ProteinSimple today announced the launch of the iCE3, a next-generation platform for quality control monitoring of protein-based therapeutics. The iCE3 platform will be unveiled at the CE Pharm 2011 conference, October 9-13, 2011, at Amelia Island, FL.
Manufacturers of protein-based therapeutics must monitor product purity closely. Imaged capillary electrophoresis (iCE) systems detect subtle impurities in protein formulations, and therefore have been adopted enthusiastically by major pharmaceutical and biotechnology companies worldwide.
The new iCE3 was designed with speed and sample throughput in mind, to help researchers address the flood of new protein biologics under development. Improved system stability helps accelerate method development and method transfer. Redesigned fluid paths increase run-to-run reproducibility. New automation options increase unattended run flexibility. The iCE3 truly powers protein research.
“It can take weeks to develop methods using older analysis techniques, and up to an hour to run each sample,” commented Susan Darling, Director of Product Management. “Our customers consistently point to rapid method development as a key advantage of iCE systems, and the iCE3 raises this bar even further. Researchers get the speed, resolution and accuracy they need, even in their most challenging samples. Our ultimate goal is to help customers achieve faster drug approvals, and the iCE3 does just that.”
The iCE3 is the second recent addition to ProteinSimple's family of products for biologics manufacturers. In May of this year, the MFI 5000 series of imaging analyzers was introduced to meet new regulatory requirements for monitoring aggregates and particles in protein formulations.
About ProteinSimple
ProteinSimple's goal is simply to help researchers gain a better understanding of proteins and their role in disease. The Company's strategy is to power protein research by making it simpler and more quantitative, ultimately revealing new insights into the true nature of proteins. ProteinSimple has built a unique portfolio of protein analysis tools including systems for traditional protein imaging, systems to probe the structure and purity of protein based therapeutics and systems that provide fresh insight into protein signaling. ProteinSimple has over 170 employees, more than 10,000 systems installed around the world and is headquartered in Santa Clara, California. For more information, visit www.proteinsimple.com.
CONTACT: Walter Ausserer, Ph.D., Vice President and General Manager of Biologics, ProteinSimple, +1-408-510-5503, walter.ausserer@proteinsimple.com